Skip to main content

Table 2 Summary of exposure to various antiretroviral drugs among people living with HIV in the US in the IMS Pharmetrics Plus Claims database stratified by regimens containing and not containing abacavir from October 1, 2009 through December 31, 2014

From: Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study

Antiretroviral drug Total exposure Exposure in antiretroviral regimens containing abacavir Exposure in antiretroviral regimens not containing abacavir
Tenofovir
 Persons with any exposure – n (%) 55,804 (76.7) Not calculated Not calculated
 Total person-years of exposure 80,939 2528 78,410
 Cumulative exposure (years) per person – mean 2.1 0.6 2.3
Lamivudine
 Persons with any exposure – no. (%) 14,106 (19.4) Not calculated Not calculated
 Total person-years of exposure 19,886 10,736 9150
 Cumulative exposure (years) per person – mean 0.5 2.2 0.3
Zidovudine
 Persons with any exposure – n (%) 6883 Not calculated Not calculated
 Total person-years of exposure 9665 2074 7591
 Cumulative exposure (years) per person – mean 0.3 0.5 0.2
Emtricitabine
 Persons with any exposure – n (%) 53,377 (73.4) Not calculated Not calculated
 Total person-years of exposure 76,466 693 75,774
 Cumulative exposure (years) per person – mean 1.9 0.2 2.2
Efavirenz
 Persons with any exposure – n (%) 29,795 Not calculated Not calculated
 Total person-years of exposure 45,930 2466 43,464
 Cumulative exposure (years) per person – mean 1.2 0.6 1.3
Nevirapine
 Persons with any exposure – n (%) 3879 Not calculated Not calculated
 Total person-years of exposure 5880 1136 4744
 Cumulative exposure (years) per person – mean 0.1 0.04 0.1
Rilpivirine
 Persons with any exposure – n (%) 4345 Not calculated Not calculated
 Total person-years of exposure 3778 103 3675
 Cumulative exposure (years) per person – mean 0 (0–0) 0 (0–0) 0 (0–0)
Atazanavir
 Persons with any exposure – n (%) 10,470 Not calculated Not calculated
 Total person-years of exposure 13,862 3026 10,836
 Cumulative exposure (years) per person – mean 0.4 0.6 0.3
Darunavir
 Persons with any exposure – n (%) 8871 Not calculated Not calculated
 Total person-years of exposure 10,394 1310 9084
 Cumulative exposure (years) per person – mean 0.3 0.3 0.3
Lopinavir
 Persons with any exposure – n (%) 5596 Not calculated Not calculated
 Total person-years of exposure 7150 1230 5920
 Cumulative exposure (years) per person – mean 0.2 0.3 0.2
Fosamprenavir
 Persons with any exposure – n (%) 1964 Not calculated Not calculated
 Total person-years of exposure 2699 698 2001
 Cumulative exposure (years) per person – mean 0.1 0.2 0.1
Raltegravir
 Persons with any exposure – n (%) 10,537 Not calculated Not calculated
 Total person-years of exposure 13,663 1731 11,932
 Cumulative exposure (years) per person – mean 0.4 0.4 0.4
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us